Evidence map›Paper›PMID 37986944›Full record

ArticleResearch square2023

FOXO1 is a master regulator of CAR T memory programming.

Alexander Doan, Katherine P Mueller, Andy Chen, Geoffrey T Rouin, Bence Daniel, John Lattin, Yingshi Chen, Brett Mozarsky, Martina Markovska, Jose Arias-Umana and 16 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 8 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors at 5 institutions in 2 countries.

Alexander DoanCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.
Katherine P MuellerDepartment of Pediatrics, Division of Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104 USA.
Andy ChenDepartment of Pathology, Stanford University, Stanford, CA 94305, USA.ORCID https://orcid.org/0000-0002-5018-355X
Geoffrey T RouinDepartment of Pediatrics, Division of Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104 USA.
Bence DanielDepartment of Pathology, Stanford University, Stanford, CA 94305, USA.ORCID https://orcid.org/0000-0002-2410-8767
John LattinCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.
Yingshi ChenDepartment of Pediatrics, Division of Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104 USA.ORCID https://orcid.org/0000-0002-5391-5103
Brett MozarskyDepartment of Pediatrics, Division of Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104 USA.
Martina MarkovskaDepartment of Pediatrics, Division of Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104 USA.
Jose Arias-UmanaDepartment of Pediatrics, Division of Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104 USA.ORCID https://orcid.org/0000-0002-7154-4780
Robert HapkeDepartment of Pediatrics, Division of Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104 USA.
Inyoung JungDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Peng XuCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.
Dorota KlyszCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.
Malek BashtiCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID https://orcid.org/0000-0003-0398-3367
Patrick J QuinnCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID https://orcid.org/0000-0002-4406-727X
Katalin SandorDepartment of Pathology, Stanford University, Stanford, CA 94305, USA.ORCID https://orcid.org/0000-0003-2892-4865
Wenxi ZhangCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.
Junior HallDepartment of Pediatrics, Division of Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104 USA.
Caleb LareauDepartment of Pathology, Stanford University, Stanford, CA 94305, USA.ORCID https://orcid.org/0000-0003-4179-4807
Stephan A GruppDepartment of Pediatrics, Division of Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104 USA.
Joseph A FraiettaAbramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID https://orcid.org/0000-0001-7900-8993
Elena SotilloCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID https://orcid.org/0000-0002-3993-1932
Ansuman T SatpathyDepartment of Pathology, Stanford University, Stanford, CA 94305, USA.ORCID https://orcid.org/0000-0002-5167-537X
Crystal L MackallCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID https://orcid.org/0000-0001-6323-4304
Evan W WeberDepartment of Pediatrics, Division of Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104 USA.
Stanford University · USUniversity of Pennsylvania · USCancer Institute (WIA) · INChildren's Hospital of Philadelphia · USCalifornia University of Pennsylvania · US

Funding

Understanding and Overcoming Resistance to Immunotherapies in Childhood CancersU54CA232568 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI MACKALL, CRYSTAL, MARIS, JOHN M · 2018 to 2022
$13.1M
Defining and overcoming intrinsic T cell dysfunction to enable pediatric immunotherapyU01CA232361 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI GRUPP, STEPHAN A., WEBER, EVAN WILLIAM · 2019 to 2019
$3.7M
4DN Interrogation of T Cell Exhaustion in CancerU01CA260852 · NCI · STANFORD UNIVERSITY · PI SATPATHY, ANSUMAN · 2020 to 2024
$2.6M
NCI NIH HHS U01 CA232361NCI NIH HHS U01 CA260852NCI NIH HHS U54 CA232568
6 · The paper itself

Abstract

Poor CAR T persistence limits CAR T cell therapies for B cell malignancies and solid tumors

Identifiers

PMID37986944
PMCPMC10659532
OpenAlexW4388441192

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.